Trials / Completed
CompletedNCT00116883
A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics
A Randomized, Double-blind, Parallel Group, Placebo Controlled, 6-week Study of the Effect of GW685698X Aqueous Nasal Spray 100mcg QD on the Hypothalamic Pituitary Adrenocortical (HPA) Axis in Children 2 to 11 Years of Age With Perennial Allergic Rhinitis (PAR).
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 2 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effect of an aqueous nasal spray investigational compound GW685698X compared to placebo on the hypothalamic pituitary adrenocortical (HPA) axis system in children 2 to 11 years of age with perennial allergic rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW685698X aqueous nasal spray |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2005-07-01
- Completion
- 2005-07-01
- First posted
- 2005-07-01
- Last updated
- 2016-09-15
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00116883. Inclusion in this directory is not an endorsement.